Propath and Lunaphore form partnership to offer hyper-plex spatial proteomics.
Building on its advanced capabilities in spatial transcriptomics and proteomics, Propath is pleased to announce a new partnership with Lunaphore, the highly innovative Swiss life sciences company, to offer its biopharmaceutical clients hyper-plex immunofluorescence staining and imaging – a powerful tool that provides unprecedented levels of contextual data from tissue samples, deeper insights into the tumour microenvironment and the ability to understand complex cell-to-cell interactions.
From its facility for spatial biology in the UK, Propath is able to perform fully automated sequential immunofluorescence (seqIF™) staining and imaging using the Lunaphore Comet instrument. The system enables robust and repeatable multiplex analysis of up to 40 different spatial markers per tissue slide without human intervention, producing images of exceptional quality and reproducibility. The platform has a wide range of research applications across all key therapeutic areas including, immuno-oncology, neuroscience, and infectious diseases.
“We are delighted to form this partnership with Lunaphore and be able to offer our biopharmaceutical clients this highly innovative technology for spatial analysis,” said Kelly Hunter, Chief Scientific Officer of Propath UK. “We look forward to working closely with Lunaphore to help our clients unlock the incredible potential of hyperplex immunofluorescence through our world-class facility dedicated to spatial biology.”
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies. For further information on Lunaphore and its products, please visit www.lunaphore.com.
Propath UK is a specialist CRO providing research services in molecular pathersology, spatial biology and histopathology for the global biopharmaceutical sector. The company off a range of technologies for spatial proteomic and transcriptomic tissue analysis, including the Lunaphore COMET™platform for hyperplex IHC analysis. Propath’sreputation has been gained over the past 40 years by providing a consistent and responsive service across thousands of pre-clinical and clinical studies. To learn more, please visit www.propath.co.uk.